U.S. Funded 120+ Biolabs Overseas, ODNI Confirms — Disclosure Reveals Years of Official Denial

A
geopolitical rift has widened following newly declassified disclosures from the Office of the Director of National Intelligence regarding the scale of U.S.-funded biological research facilities overseas. The release of these documents has intensified international debate over strategic transparency, oversight failures, and the operational intent of security partnerships in active conflict zones.

According to the declassified materials, the United States government has historically provided funding to more than 120 biological laboratories across more than 30 countries, including facilities located in Ukraine. Tulsi Gabbard, who serves as Director of National Intelligence until June 30, 2026, framed the disclosure as an essential step toward transparency, directly linking the findings to administrative efforts to eliminate federally funded gain-of-function research. “The information surrounding the existence, history, locations and funding of these US-funded biolabs has been intentionally covered up by powerful people,” Gabbard stated during the release, alleging that previous officials obscured the scope of these operations from the public.

The roots of the controversial network trace back to post-Cold War defense treaties initiated under the 1991 Cooperative Threat Reduction program. For decades, the Pentagon’s Defense Threat Reduction Agency channeled hundreds of millions of dollars into upgrading foreign medical and veterinary facilities, particularly in former Soviet republics. The officially stated purpose of these initiatives was to secure dangerous pathogens left behind by the Soviet Union’s biological warfare program and to establish early warning systems for natural global pandemics.

However, the geographic placement of these laboratories has drawn sharp criticism from military analysts and foreign governments, who point out that dozens of facilities handling high-consequence pathogens sit directly along the borders of major U.S. adversaries like Russia and China. Critics argue that operating decentralized networks in countries with historically high corruption indices created severe oversight vulnerabilities. This argument gained significant traction after the declassified files revealed that facilities like the Kherson Diagnostic Laboratory received approximately 1.7 million dollars in U.S. financial support while pathogen handling permits were listed as pending, with documentation to be completed upon formal transfer of custody — a procedural sequencing condition standard to the program, but one that critics argue enabled research to proceed in a regulatory grey zone.

The disclosure has also reignited scrutiny over the early stages of the Russia-Ukraine conflict, when initial reports regarding the laboratories were met with fierce denials from Washington. U.S. State Department and Pentagon officials originally maintained that the United States did not operate biological weapons labs in Ukraine, a defense that critics now describe as a distinction that functioned as a lie by omission, obscuring the extent of U.S. financial involvement. While American personnel did not directly own or manage the facilities, many of the facilities received substantial U.S. funding for infrastructure, equipment, training, and research activities.

This long-standing policy of denial has drawn criticism from within European political circles as well, where former lawmakers are questioning the strategic risks associated with these programs. Sevim Dagdelen, former German MP and foreign policy spokeswoman for Germany’s Sahra Wagenknecht Alliance, publicly challenged the lack of institutional transparency regarding NATO’s awareness of the network. “What did NATO know, and what did the federal government know, which has become the largest financier of Ukraine after the financial withdrawal of the US?” Dagdelen asked. “Those who previously raised these issues,” she added, “were subjected to slander and threats, labelled conspiracy theorists or Russian agents.”

ALSO READ: Inside the Fall of Tulsi Gabbard: How the Iran War Ended America’s Top Spy Chief

The escalation of the information war surrounding the laboratories was marked by intense personal risks for those involved in exposing the program. Lieutenant General Igor Kirillov, the former head of Russia’s Radiation, Chemical, and Biological Defense Troops, was among the most prominent officials to publicly present allegations regarding Pentagon funding of biological laboratories in Ukraine. Kirillov was killed in Moscow in December 2024 in a bombing attack claimed by Ukraine’s SBU intelligence service. Western governments and Ukraine had characterised many of his claims as disinformation — a position that now sits in tension with the ODNI’s own disclosures. Western governments had imposed sanctions on Kirillov prior to his death, citing alleged use of chemical weapons against Ukrainian forces.

Retired U.S. Army Lieutenant General Michael Flynn, former National Security Advisor to President Trump, has separately raised alarm over what he characterised as systemic oversight failures in U.S. financial flows to Ukraine. In a widely circulated 2023 statement, Flynn asserted that Ukraine “is a hub for human trafficking… a hub for narcotics trafficking… a hub for weapons trafficking… we know about our bio labs… and there’s a lot of money just flowing in… it’s money laundering, you name it.” Flynn’s allegations remain disputed and have not been independently verified, but have gained renewed circulation following the ODNI disclosure.

Outside of Europe, allegations concerning the potential risks associated with international biological research networks continue to fuel debate between Washington and several non-Western governments. Some commentators and independent researchers have argued that outbreaks of African Swine Fever and avian influenza warrant further scrutiny in the context of broader discussions about biological security and pathogen research. However, no conclusive evidence has established a link between these outbreaks and U.S.-funded biological laboratories, and public health authorities continue to attribute such outbreaks to naturally occurring disease transmission and other established epidemiological factors.

The disclosure has intensified international debate regarding biological security, transparency, and state accountability. Supporters of the programs continue to describe them as legitimate biodefense and public health partnerships, while critics argue that the newly released information raises unresolved questions about oversight, risk management, and public disclosure. The long-term implications of the disclosures remain the subject of ongoing political and policy debate. The Pentagon has long maintained that the Cooperative Threat Reduction programme was designed exclusively to neutralise dangerous Soviet-era pathogens and prevent proliferation — a position the newly declassified evidence neither fully confirms nor fully refutes. The ongoing policy adjustments in Washington, including stricter directives against global gain-of-function funding, suggest that the systemic fallout from these disclosures will influence international military and scientific frameworks for years to come.